GYRE THERAPEUTICS, INC. (GYRE) Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Gyre Therapeutics, Inc. NASDAQ:GYRE Healthcare · Biotechnology
Mkt Cap $507.93M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
Gyre Therapeutics management will participate in fireside chats at two September investor conferences in New York: the Cantor Global Healthcare Conference on September 9, 2026 at 9:45 a.m. ET and the Morgan Stanley Healthcare Conference on September 16, 2026 at 1:05 p.m. ET.
Both chats will be webcast live, with replays archived for 30 days on the investor relations section of the Gyre website.
The release contains no new financial or clinical data; background sections reiterate that the F351 (hydronidone) NDA for CHB-induced liver fibrosis was accepted by China's NMPA in May 2026 and that Gyre owned 69.7% of Gyre Pharmaceuticals as of June 30, 2026.
• 1mo ago AI analysis › Press Release ⚠ 3
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million, roughly flat with the prior year, while reaffirming full-year guidance of $100.5 to $111.0 million.
Revenue from commercial products was mixed, with ETUARY sales rising 19% to $28.0 million offset by declines in Etorel and Contiva following China's centralized procurement program.
The company closed the $300 million all-stock acquisition of Cullgen in May, bringing a new pipeline of targeted protein degraders, and recorded a $4.8 million milestone payment for the acceptance of its NDA for F351 in China.
• 2mo ago AI analysis › Press Release
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Gyre Therapeutics appointed three new members to its Board of Directors effective August 1, 2026: Chief Scientific Officer Dr. Yue Xiong, biopharma consultant Maxwell Kirkby, and Tactus AI CEO Dr. Claire Weston.
The new directors bring deep expertise in cross-border drug development, corporate governance, and targeted protein degradation, with Kirkby joining the Compensation Committee and Weston joining the Audit Committee.
These appointments expand the Board's scientific and operational capabilities as Gyre advances its pipeline of therapies for fibrosis, cancer, and inflammation.
• 3mo ago AI analysis › Press Release ⚠ 2
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Gyre Therapeutics reported Q1 2026 revenue of $22.5 million, up 2% year-over-year, but posted a GAAP net loss of $9.9 million or $(0.10) per share driven by increased R&D, acquisition costs, and stock-based compensation. The company reaffirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million and ended the quarter with $79.2 million in total cash, cash equivalents, and deposits.
Operationally, Gyre completed the acquisition of Cullgen Inc. in an approximately $300 million all-stock transaction, expanding its capabilities into targeted protein degradation for cancer and inflammatory diseases.
On the pipeline front, the company submitted a New Drug Application for F351 to China’s CDE for CHB-associated liver fibrosis, securing priority review designation, while also initiating a Phase 2/3 trial for ETUARY in radiation-induced lung injury.
• 5mo ago AI analysis › Press Release ● Critical ⚠ 2
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics closed its acquisition of Cullgen in an all-stock transaction valued at approximately $300 million, creating a fully integrated biopharmaceutical company with operations in the U.S. and China.
Dr. Ying Luo, former CEO of Cullgen, was appointed President and Chief Executive Officer of Gyre, while Ping Zhang continues to serve as Chairman of the Board.
The combined company features a commercial-stage asset in ETUARY and a robust pipeline including the targeted protein degrader platform from Cullgen, alongside Phase 3 programs for liver and lung fibrosis.
• 5mo ago AI analysis › 
